title: Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
abstract: OBJECTIVE
  The primary objective of the study was to compare the percentage of men with mean serum total T (C(ave(0-24))) within normal range during the 24-h pharmacokinetic (PK) sampling period on Days 14 and 15.
  
  
  METHODS
  Treatment with a new testosterone (T) buccal system, (Striant), 30 mg twice daily was compared to a transdermal gel delivery system, (T-gel) [AndroGel 5 g containing 1% (50 mg) T] daily for 14 days in T-deficient men. Safety parameters included laboratory assessments and collection of adverse events. Patients were otherwise healthy T-deficient men with total T <or= 8.7 nmol/L (<or= 2.5 ng/mL).
  
  
  RESULTS
  Twenty-six of the 28 patients enrolled (0.93 +/- 0.38 ng/mL) for T-gel, which was greater completed the 24-h PK assessment. Of the evaluable patients, 92.3% of T buccal system and 83.3% of T-gel patients had C(ave(0-24)) within the normal range of 10.4-36.4 nmol/L (3.0-10.5 ng/mL). Mean total T values were not different in the T buccal system group (C(ave(0-24)) 16.7 +/- 4.7 nmol/L; 4.8 +/- 1.4 ng/mL) compared to the T-gel group (C(ave(0-24)) 15.9 +/- 4.8 nmol/L; 4.6 +/- 1.4 ng/mL). All T values returned to baseline levels after the study drug was stopped. Serum LH and FSH levels decreased, and E(2) increased as expected following T administration. Differences in DHT concentrations between treatment groups were significant (p = 0.012) with mean DHT levels on Day 14 of 1.9 +/- 1.4 nmol/L (0.55 +/- 0.42 ng/mL) for the T buccal system and 3.2 +/- 1.3 nmol/L than the upper level of normal (2.9 nmol/L; 0.85 ng/mL). Statistically significant differences were seen in the mean T/DHT ratio on Days 14 and 15 with the T buccal system (9.3) and T-gel (5.0) (normal 9-12) (Day 14, p < 0.00001; Day 15, p < 0.0001). All adverse events were mild to moderate in severity. Three of 12 adverse events significant adverse effects in T-deficient men. The T were considered related to the study drug and included headache (1 for each of the T buccal system and T-gel), and breast pain (T-gel).
  
  
  CONCLUSIONS
  In this short-term study, the T buccal system produced steady-state T levels comparable to those with T-Gel without buccal system provides an additional safe, effective and convenient option for testosterone replacement therapy in hypogonadal men.
authors.affiliation: The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. adobs@jhu.edu
authors.forename: A S
authors.initials: AS
authors.lastname: Dobs
authors.forename: A M
authors.initials: AM
authors.lastname: Matsumoto
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.forename: M S
authors.initials: MS
authors.lastname: Kipnes
mesh_terms: D000278:Administration, Buccal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D016503:Drug Delivery Systems; D005782:Gels; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000008:administration & dosage* / Q000172:deficiency / Q000493:pharmacokinetics*
chemical_list: D005782:Gels; D013739:Testosterone